Articles

Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromes

Department of Hematology, Radboud university medical center, Nijmegen, the Netherlands
Department of Hematology, University Medical Centre, Groningen, the Netherlands
Epidemiology and Cancer Statistics Group, University of York, UK
Department of Hematology, Radboud university medical center, Nijmegen, the Netherlands
St. James’s Institute of Oncology, Leeds Teaching Hospitals, UK
Department of Medicine, Division of Hematology, Karolinska Institutet, Stockholm, Sweden
Center of Hematology and Bone Marrow Transplantation, Fundeni Clinical Institute, Bucharest, Romania
Department of Medicine, Division of Hematology, University of Patras Medical School, Greece
Department of Hematology, University Medical Centre, Groningen, the Netherlands
Department of Clinical Hematology, Institute of Hematology & Blood Transfusion, Prague, Czech Republic
Department of Hematology – Cancer Center Amsterdam VU University Medical Center, The Netherlands
Department of Medicine, Section of Hematology and Coagulation, Sahlgrenska University Hospital, Göteborg, Sweden
Department of Haematology, Aberdeen Royal Infirmary, UK
Department of Haematology, Blackpool Victoria Hospital, Lancashire, UK
Department of Haematology, Airedale NHS trust, UK
Department of Hematology, Laikon General Hospital, National and Kapodistrian University of Athens, Greece
Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Masaryk University, Czech Republic
Department of Hematology, Radboud university medical center, Nijmegen, the Netherlands
Department of Hematology, Radboud university medical center, Nijmegen, the Netherlands
Department of Hematology, Radboud university medical center, Nijmegen, the Netherlands
Department of Laboratory Medicine, Hepcidinanalysis.com, and Radboudumc expertise center for iron disorders, Radboud university medical center, Nijmegen, the Netherlands and
Department of Hematology, University Medical Centre, Groningen, the Netherlands
Nijmegen Center for Molecular Life Sciences, Department of Tumor Immunology, Radboud university medical center, the Netherlands
Vol. 103 No. 1 (2018): January, 2018 https://doi.org/10.3324/haematol.2017.171884